Abstract: Novel chemical compounds which are heparin fragments with a molecular weight of from 2,000 to 5,500 covalently bound to antithrombin III, and their use in medicine.

Abstract: This invention relates to a device for dosing and mixing of two or more liquids. According to the invention, the liquids are led to a chamber (26) where they are mixed, an outlet (30) from the chamber being closed at the same time. When the chamber (26) has been filled, the outlet (30) is opened while the inlets (21, 22) for the starting liquids are simultaneously closed, and when the chamber (26) has been emptied, the outlet (30) is closed again and the inlet or inlets (21, 22) are opened. This cyclic process is repeated any desired number of times. The chamber has a variable volume, and changes of the volume are sensed by a sensor (28), which controls the opening and closing of the inlets and the outlets.The device for carrying out the method is provided with a mechanical bistable flip-flop device, which in one of its stable positions opens the inlets (21, 22) and closes the outlet (30), and in the other stable position closes the inlets and opens the outlet.

Abstract: Sterile, glycerol free lipid emulsion suitable for parenteral administration and including alanine in an amount sufficient to provide pharmaceutically acceptable osmolality.

Abstract: An emulsifier adapted for use in a nutritive oil-in-water emulsion suitable for parenteral administration is produced by extracting vegetable lecithin with alkyl alcohols having from 1 to 3 carbon atoms, or mixtures thereof, followed by fractional precipitation at specific temperatures and concentrations effective to cause the removal of toxic materials. The alcohol soluble phospholipid fraction produced by the process contains an increased level of phosphatidyl choline and reduced levels of phosphatidyl ethanolamine, inositol phospholipids, phosphatidic acid and glycolipids.

Abstract: New thrombin inhibiting N.sup..alpha. -arylsulfonyl-p-guanidinophenylalanine amides of the formula ##STR1## wherein Ar is a substituted aryl and R.sub.1 and R.sub.2 are an alkyl group having 1-5 carbon atoms or together with the amine nitrogen form an heterocyclic ring, in racemate form as well as in form of optical active antipodes, theirs pharmaceutically acceptable salts, methods for their preparation, pharmaceutical composition and diagnostical preparation containing these compounds, use of the compounds in treatments of thrombosis and methods of treatment of thrombosis as well as methods for determination of thrombin concentration in blood.

Abstract: A novel complex of carrageenan and a member of the group consisting of emepronium, doxycycline, and propranolol, pharmaceutical preparations containing such a complex, and its use in medicine.

Abstract: Method and composition for enhancing protein anabolism in an hypercatabolic mammal. The method comprises parenterally administering to the mammal nutritionally sufficient sources for amino acids, carbohydrates and lipids, the lipids comprising a controlled triglyceride source which, on hydrolysis, yields both long chain fatty acids and medium chain fatty acids, preferably about 20 to 80% long chain fatty acids and about 80 to 20% medium chain fatty acids. In one embodiment, the composition has the additional benefit of being capable of providing more than 60% of the total caloric requirements of the mammal via the lipid source without immunological impairment of the reticuloendothelial system of the mammal.

Abstract: The invention relates to an oligosaccharide which contains 4-8 monosaccharide units and which is characterized in that it contains at least one glucosamine unit which is 3-0-sulfated, and at least one additional glucosamine unit, whereby these units are linked via an intermediate monosaccharide unit, which is bound to the reducing end of the 3-0-sulfated glucosamine unit. The invention further relates to a pharmaceutical composition containing one or more such oligosaccharides, and to a process for the preparation of these oligosaccharides.

Abstract: Novel antifibrinolytically active compounds of the formula ##STR1## and therapeutically acceptable salt thereof, whereinR.sup.1 is selected from the group consisting of(a) alkyl groups containing 1-4 carbon atoms,(b) alkoxy groups containing 1-4 carbon atoms, ##STR2## R.sup.2 is selected from the group consisting of (a) H,(b) alkyl groups containing 1-4 carbon atoms,(c) --COOR.sup.3, wherein R.sup.3 is an alkyl group containing 1-4 carbon atoms,(d) --CONR.sup.4 R.sup.5, wherein R.sup.4 and R.sup.5 are the same or different alkyl groups containing 1-3 carbon atoms;or wherein R.sup.1 and R.sup.